Immunology Program

About Creyon Bio

Creyon Bio is a private, pre-clinical biotech company pioneering a novel approach to RNA drug delivery using aptamers and artificial intelligence. Its core technology platform aims to overcome key limitations of traditional antibody-based delivery and lipid nanoparticles by enabling precise, cell-specific targeting of therapeutic payloads like siRNA and ASOs. The company has established preclinical proof-of-concept in three therapeutic areas—immunology, CNS, and neuromuscular diseases—and is advancing a wholly-owned pipeline. Creyon represents a convergence of next-generation delivery science and computational drug design, positioning it to develop potentially safer and more effective RNA therapies.

About Ignite Biomedical

Ignite Biomedical is a private, pre-revenue biotech company pioneering an AI-driven approach to precision medicine. Its core technology is a quantitative AI platform used to de-risk and accelerate the discovery of mRNA-based diagnostics and precision drug targets, with active programs in immunology, autism, PTSD, and substance use disorder. The company's value proposition centers on drastically reducing diagnostic delays, improving treatment efficacy prediction, and condensing pre-clinical drug development timelines to 1-2 years. Its mission is to fulfill the broken promises of precision medicine by delivering pragmatic, patient-focused solutions.

About Seragon Biosciences

Seragon Biosciences is a private, pre-revenue biotech firm leveraging advanced AI and gene therapy platforms to target aging, metabolic disorders, and immunology. The company's core technologies include the GenomeScore™ AI platform for measuring aging and a hybrid gene therapy platform for efficient gene delivery. Operating in the high-growth longevity and gene therapy sectors, Seragon appears to be in a pre-clinical or discovery-stage, building its scientific foundation and seeking partnerships to advance its research programs.

Therapeutic Areas